Management of postmenopausal women: what the clinician can rely on?

Abstract

This review discusses the reasons for the low use of menopausal hormone therapy (MHT) in postmenopausal women, results of recent evidence-based studies showing favorable benefit/risk profile associated with MHT in women aged 50--59 years and/or menopause lasting less than 10 years, as well as ways for minimizing risks of the therapy.

Keywords

• постменопауза
• менопаузальная гормональная терапия
• рандомизированные клинические исследования
• postmenopause, menopausal hormone therapy, randomized clinical trials